Literature DB >> 4085520

Renal elimination of the hypoxic cell radiosensitizer misonidazole in Wistar rats: influence of some drugs on its excretion.

G Akel, P Canal, G Soula.   

Abstract

The hypoxic cell radiosensitizing drug, misonidazole (Miso) (Ro 07-0582) and its demethylated metabolite were administered to Wistar rats at different dose levels to examine their renal elimination. The data were consistent with a model in which Miso is eliminated mainly after biotransformation into desmethylmisonidazole (Demiso) which is eliminated according to its renal clearance. The study of Miso renal elimination process shows a tubular reabsorption. So we analyzed the interaction of various drugs on urinary 24 hours elimination of this radiosensitizer. Following results were observed: Furosemide and acetazolamide do not change the rate of renal elimination of the drug; Soludactone increases the elimination level of unmetabolized Miso (p less than 0.01); Under probenecid treatment, the elimination of Miso and its O-demethylated derivative are increased; On the other hand, after a pretreatment with phenobarbital, the urinary level of desmethylmisonidazole is strongly increased (p less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4085520     DOI: 10.1007/BF03189740

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  17 in total

1.  Misonidazole-a drug for trial in radiotherapy and oncology.

Authors:  S Dische; M I Saunders; I R Flockhart; M E Lee; P Anderson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-06       Impact factor: 7.038

2.  The effect of oral phenobarbitone on hepatic microsomal cytochrome P-450 and demethylation activity in rats fed normal and low protein diets.

Authors:  W J Marshall; A E McLean
Journal:  Biochem Pharmacol       Date:  1969-01       Impact factor: 5.858

3.  The pharmacokinetics of misonidazole in the dog.

Authors:  R A White; P Workman; L S Freedman; L N Owen; N M Bleehen
Journal:  Eur J Cancer       Date:  1979-10       Impact factor: 9.162

4.  Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice.

Authors:  P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

5.  Misonidazole blood and cerebrospinal fluid kinetics in monkeys following intravenous and intrathecal administration.

Authors:  D Gangji; D G Poplack; J Schwade; J H Wood; J M Strong
Journal:  Eur J Cancer       Date:  1981-01       Impact factor: 9.162

6.  The neurotoxicity of misonidazole: potential modifying role of phenytoin sodium and dexamethasone.

Authors:  T H Wasserman; T L Phillips; G Van Raalte; R Urtasun; J Partington; D Koziol; J G Schwade; D Gangji; J M Strong
Journal:  Br J Radiol       Date:  1980-02       Impact factor: 3.039

7.  Reduction of the renal toxicity of cis-dichlorodiammineplatinum(II) by probenecid.

Authors:  D A Ross; G R Gale
Journal:  Cancer Treat Rep       Date:  1979-05

8.  Nonlinear pharmacokinetics of misonidazole and desmethylmisonidazole in the isolated perfused rat liver.

Authors:  M E McManus; A Monks; J M Collins; R White; J M Strong
Journal:  J Pharmacol Exp Ther       Date:  1981-12       Impact factor: 4.030

9.  Kinetics and renal handling of cefonicid.

Authors:  D Pitkin; J Dubb; P Actor; F Alexander; S Ehrlich; R Familiar; R Stote
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

10.  Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice.

Authors:  P Workman
Journal:  Br J Cancer       Date:  1979-09       Impact factor: 7.640

View more
  1 in total

1.  Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model.

Authors:  Nicolas Christian; Anne Bol; Marc De Bast; Daniel Labar; John Lee; Pierre Mahy; Vincent Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03-03       Impact factor: 9.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.